RxDoctor Payments Data

Berdj Stepanian, DPM

Foot Surgery · White Plains, NYNPI 1851398374

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.3% of the total across 488 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $6,158, 3.0 times the $2,020 reported in 2019. Among foot surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,715in general payments, 2019–2025

Across 488 payments — averaging $52.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$4K
  • Next Science LLC$4K
  • Smith+Nephew$3K
  • Paratek Pharmaceuticals, Inc.$2K
  • Stryker$2K
  • AbbVie$1K
  • plus $10K from 44 others

What the payments were for

  • Speaking & faculty fees$2501%
  • Food & beverage$24,26094%
  • Education$1,2055%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,715 in reported general payments places this provider in the 95th percentile of 294 foot surgery providers in New York.

See all foot surgery providers in New York

Medicare billing

Part B allowed, 2024
$106,855
Medicare patients
225
Services billed
1,373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuzyraOmadacycline Tosylate12$49,920
Ammonium Lactate29$460
Cephalexin14$154
Gabapentin14$50

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Paratek Pharmaceuticals, Inc.Nuzyra$2,144$49,92012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 294 foot surgery providers in New York.

Other foot surgery in White Plains

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →